Stanley Druckenmiller Arcellx, Inc. Transaction History
Duquesne Family Office LLC
- $4.07 Billion
- Q2 2025
Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
219Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$360 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$305 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$290 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$272 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$235 Million4.37% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.39B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...